All data are based on the daily closing price as of October 9, 2024

Oneness Biotech’s SNS812 Shows Strong Efficacy Against COVID-19 Variants in Phase 2 Trials

The new nucleic acid drug demonstrates promising results, outperforming existing treatments like Pfizer's Paxlovid
Taiwan
o 4743.TWO Mid and Small Cap 2000
Share this on

Oneness Biotech and Zhongtian Shanghai announced that their newly developed COVID-19 treatment, SNS812, has successfully achieved key benchmarks in its Phase 2 clinical trials. The nucleic acid drug demonstrated strong safety and significant clinical efficacy against highly immune-evasive COVID-19 variants, including JN.1, KP1-4, and LB.1, which account for 90% of strains in the trial.

Conducted at National Taiwan University Hospital and other top medical institutions, the trial followed rigorous international standards. SNS812, administered through aerosol inhalation, outperformed a placebo in reducing the time to symptom resolution, including common symptoms like fever, sore throat, and shortness of breath. The trial also found the drug reduced the median time for virus positive-to-negative conversion to just 2.9 days in the high-dose group.

As COVID-19 continues to mutate, current vaccines and treatments struggle to keep pace, but SNS812’s broad efficacy across multiple variants positions it as a potential game changer. Oneness Biotech aims to pursue international collaborations and regulatory approvals for emergency use authorization (EUA) and global distribution of SNS812 in major markets. The results offer hope for improved COVID-19 management in the face of persistent viral mutations.

 

 

 

Share this on
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top